Trading--Leveraged Equity · NASDAQ · USD · Data as of 2026-07-30
AUM
$83.66M
Expense ratio
0.95%
Yield
0.32%
YTD return
+26.38%
Last price
$98.49
Leveraged · Coverage 75% · medium
Today
40.0
Outlook
50.6
Block A (composite-derived)
57.5
Block C (market behavior)
31.4
Today overlay (Block D)
0.0
Outlook overlay (Block D)
0.0
today_score = clip(0,100, 50 + 0.15·(A−50) + 0.60·(C−50) + D_today). Block B (holdings rollup) is in Phase 3 development; β=0 caps the natural range at ~12.5–87.5 in Preview v0.9. Formula version tide-etf-v1.0.0.
57.5
Coverage 75% · medium
Liquidity
73.8
Expenses
45.0
Performance
65.6
Volatility
63.4
Dividend
18.0
Concentration
70.0
Smart Money
—
Activist
—
Formula version composite-v1.0.0. Axes hover to see why a sub-score is missing.
ProShares Ultra Nasdaq Biotechnology (BIB) is an exchange-traded fund from ProShares in the Mixed asset class. Launched in 2010. Assets under management: 75,861,616.
Bullish Whales composite rating: 57 out of 100. Evidence coverage 75% across 6 of 8 axes. Strongest axes: liquidity, concentration, performance.
Annualized one-year realized volatility 39%, classified high. Weakest axes: dividend, expenses.
Top-10 weight 0%, diversified, led by AMGN. Trailing yield 0%.
etf_composite_score_current · composite_score, concentration_score, confidence, coverage_pct, dividend_score, expenses_score, liquidity_score, performance_scoreetf_fundamentals_td · dividend_frequency, yieldetf_holdings_top10 · holding_symbol, weightetf_universe · asset_class, aum_usd, fund_type, inception_date, issuer, name, ticker, volatility_1yProShares Ultra Nasdaq Biotechnology is a leveraged exchange-traded fund (ETF) designed to amplify investor exposure to the Nasdaq Biotechnology Index. This financial instrument aims to provide two times the daily performance of the index before fees and expenses, making it a strategic option for investors seeking enhanced exposure to biotechnology stocks. It primarily tracks companies involved in biotechnology and pharmaceuticals, sectors known for their focus on medical research, biological sciences, and drug innovation. This ETF plays a significant role in the financial market by enabling investors to capitalize on the rapid advancements and potential high growth within the biotechnology industry. With its leveraged nature, ProShares Ultra Nasdaq Biotechnology is particularly suited for short-term strategies, allowing investors to maximize gains from daily index fluctuations. Managed by ProShares, a prominent provider of leveraged and inverse ETFs, this fund exemplifies the versatility and targeted approach that sophisticated investors utilize to navigate the dynamic biotech landscape.
30-day change
$10.00M
90-day change
—
Current AUM: $83,660,240. AUM change is computed from rolling daily fundamentals snapshots; it reflects total net-asset deltas (creations/redemptions + market value moves), not pure share creations.
Fund documents (fact sheets, prospectuses, semi-annual reports) for BIB are coming soon. The BW fund-document archive will surface PDFs alongside a metadata index for searchability.